ProMIS Neurosciences Inc (PMN)

Currency in USD
13.685
-0.835(-5.75%)
Real-time Data·
Unusual trading volume
PMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.25014.600
52 wk Range
6.27027.400
Key Statistics
Prev. Close
14.52
Open
14.6
Day's Range
13.25-14.6
52 wk Range
6.27-27.4
Volume
205.98K
Average Volume (3m)
80.69K
1-Year Change
-34.9839%
Book Value / Share
6.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PMN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.361
Upside
+173.01%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

ProMIS Neurosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.361
(+173.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy69.00+407.54%35.00MaintainJul 29, 2026
Chardan
Buy33.00+142.74%20.00MaintainJul 28, 2026
Chardan
Buy20.00+47.11%-New CoverageJul 27, 2026
H.C. Wainwright
Buy18.00+32.40%-MaintainJul 15, 2026
Roth/MKM
Buy19.00+39.76%-New CoverageJul 07, 2026

Earnings

Latest Release
May 12, 2026
EPS / Forecast
-1.26 / -0.18
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PMN Income Statement

Compare PMN to Peers and Sector

Metrics to compare
PMN
Peers
Sector
Relationship
P/E Ratio
−3.0x−2.4x−0.3x
PEG Ratio
0.00−0.180.00
Price/Book
2.0x1.4x2.6x
Price / LTM Sales
-2.5x3.0x
Upside (Analyst Target)
134.6%925.2%56.3%
Fair Value Upside
Unlock5.5%9.8%Unlock

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.63K0.06%66.03K
Other Institutional Investors
10.00M99.94%117.14M
Public Companies & Retail Investors
0.000.00%0.00
Total
10M100.00%117.21M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group Ltd.14.42%1,292,75715,151
Deep Track Capital, LP9.32%835,6559,794

People Also Watch

85.18
ECHO
-0.87%
12.52
FLNC
-0.79%
28.880
CUE
-4.53%
2.87
AIIO
-5.90%
215.56
SIMO
-2.65%

FAQ

What Is the ProMIS Neurosciences (PMN) Stock Price Today?

The ProMIS Neurosciences stock price today is 13.685 USD.

What Stock Exchange Does ProMIS Neurosciences Trade On?

ProMIS Neurosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ProMIS Neurosciences?

The stock symbol for ProMIS Neurosciences is "PMN."

What Is the ProMIS Neurosciences Market Cap?

As of today, ProMIS Neurosciences market cap is 130.210M USD.

What Is ProMIS Neurosciences's Earnings Per Share (TTM)?

The ProMIS Neurosciences EPS (TTM) is -13.360.

When Is the Next ProMIS Neurosciences Earnings Date?

ProMIS Neurosciences will release its next earnings report on May 12, 2026.

From a Technical Analysis Perspective, Is PMN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has ProMIS Neurosciences Stock Split?

ProMIS Neurosciences has split 2 times.

How Many Employees Does ProMIS Neurosciences Have?

ProMIS Neurosciences has 11 employees.

What is the current trading status of ProMIS Neurosciences (PMN)?

As of Jul 29, 2026, ProMIS Neurosciences (PMN) is trading at a price of 13.685 USD, with a previous close of 14.520 USD. The stock has fluctuated within a day range of 13.250 USD to 14.600 USD, while its 52-week range spans from 6.270 USD to 27.400 USD.

What Is ProMIS Neurosciences (PMN) Price Target According to Analysts?

The average 12-month price target for ProMIS Neurosciences is 37.361 USD, with a high estimate of 69.12750248 USD and a low estimate of 17.96109612 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +173.01% Upside potential.

What Is the PMN Premarket Price?

PMN's last pre-market stock price is 14.560 USD. The pre-market share volume is 4,980.000, and the stock has decreased by 0.040, or 0.280%.

What Is the PMN After Hours Price?

PMN's last after hours stock price is 14.330 USD, the stock has decreased by -0.190, or -1.310%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.